PLoS ONE (Jan 2017)

Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure.

  • Takehiro Kamo,
  • Hiroshi Akazawa,
  • Wataru Suda,
  • Akiko Saga-Kamo,
  • Yu Shimizu,
  • Hiroki Yagi,
  • Qing Liu,
  • Seitaro Nomura,
  • Atsuhiko T Naito,
  • Norifumi Takeda,
  • Mutsuo Harada,
  • Haruhiro Toko,
  • Hidetoshi Kumagai,
  • Yuichi Ikeda,
  • Eiki Takimoto,
  • Jun-Ichi Suzuki,
  • Kenya Honda,
  • Hidetoshi Morita,
  • Masahira Hattori,
  • Issei Komuro

DOI
https://doi.org/10.1371/journal.pone.0174099
Journal volume & issue
Vol. 12, no. 3
p. e0174099

Abstract

Read online

Emerging evidence has suggested a potential impact of gut microbiota on the pathophysiology of heart failure (HF). However, it is still unknown whether HF is associated with dysbiosis in gut microbiota. We investigated the composition of gut microbiota in patients with HF to elucidate whether gut microbial dysbiosis is associated with HF. We performed 16S ribosomal RNA gene sequencing of fecal samples obtained from 12 HF patients and 12 age-matched healthy control (HC) subjects, and analyzed the differences in gut microbiota. We further compared the composition of gut microbiota of 12 HF patients younger than 60 years of age with that of 10 HF patients 60 years of age or older. The composition of gut microbial communities of HF patients was distinct from that of HC subjects in both unweighted and weighted UniFrac analyses. Eubacterium rectale and Dorea longicatena were less abundant in the gut microbiota of HF patients than in that of HC subjects. Compared to younger HF patients, older HF patients had diminished proportions of Bacteroidetes and larger quantities of Proteobacteria. The genus Faecalibacterium was depleted, while Lactobacillus was enriched in the gut microbiota of older HF patients. These results suggest that patients with HF harbor significantly altered gut microbiota, which varies further according to age. New concept of heart-gut axis has a great potential for breakthroughs in the development of novel diagnostic and therapeutic approach for HF.